MedTrace Logo

Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial

NCT01858077 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1845

Last updated 2019-01-09

No results posted yet for this study

Summary

To evaluate the efficacy and performance in an all-comers contemporary population of the ABSORB bioresorbable vascular scaffolds (BVS) strategy versus the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus eluting coronary stent system in the treatment of coronary lesions.

Conditions

Interventions

DEVICE

ABSORB BVS™

Bioresorbable scaffold

DEVICE

XIENCE™

Drug eluting metallic stent

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Principal Investigators

  • Joanna Wykrzykowska, MD, PhD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  • Rob de Winter, MD, PhD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  • Jan Piek, MD, PhD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  • Jan Tijssen, PhD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  • Jose Henriques, MD, PhD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2017-12-31
Completion
2020-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01858077 on ClinicalTrials.gov